Skip to main content
To refer to this page use:
Abstract: We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. Deep whole-exome sequencing revealed recurrent somatic mutations in KRAS, TP53, CDKN2A, SMAD4, RNF43, ARID1A, TGFβR2, GNAS, RREB1, and PBRM1. KRAS wild-type tumors harbored alterations in other oncogenic drivers, including GNAS, BRAF, CTNNB1, and additional RAS pathway genes. A subset of tumors harbored multiple KRAS mutations, with some showing evidence of biallelic mutations. Protein profiling identified a favorable prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway scores. Associations of non-coding RNAs with tumor-specific mRNA subtypes were also identified. Our integrated multi-platform analysis reveals a complex molecular landscape of PDAC and provides a roadmap for precision medicine.
Publication Date: Aug-2017
Citation: Cancer Genome Atlas Research Network. Electronic address:, Cancer Genome Atlas Research Network. (2017). Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.. Cancer cell, 32 (2), 185 - 203.e13. doi:10.1016/j.ccell.2017.07.007
DOI: doi:10.1016/j.ccell.2017.07.007
ISSN: 1535-6108
EISSN: 1878-3686
Pages: 185 - 203.e13
Language: eng
Type of Material: Journal Article
Journal/Proceeding Title: Cancer cell
Version: Final published version. This is an open access article.

Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.